Tauroursodeoxycholate [14605-22-2]
Referência NB-64-14544-1mL
Tamanho : 1mLx10mM(inDMSO)
Marca : Neo Biotech
Contactar o distribuidor local :
Telefone : +1 850 650 7790
Tauroursodeoxycholate (Synonyms: Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, Taurolite)
Catalog No. T2532 Copy Product Info
Purity: 99.93%
Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
Tauroursodeoxycholate
Copy Product InfoSynonyms Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, Taurolite
Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
Cas No. 14605-22-2
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis. |
| In vitro | METHODS: HeLa cells overexpressing the WDR45 mutation were treated with Tauroursodeoxycholate (200 µM) for 24 h, and the expression levels of target proteins were measured by Western Blot. RESULTS: Inhibition of ER stress with Tauroursodeoxycholate significantly reduced the phosphorylation of p38 and LAMP2A as well as the punctate formation of mCherry KFERQ in cells expressing mutant WDR45. [1] METHODS: Undifferentiated neural stem cells NSCs were treated with Tauroursodeoxycholate (100 µM) for 24 h and cell proliferation was detected by Flow cytometry via BrdU. RESULTS: BrdU incorporation increased significantly after incubation with Tauroursodeoxycholate, and Tauroursodeoxycholate regulated cell proliferation. Tauroursodeoxycholate regulates cell proliferation.[2] |
| In vivo | METHODS: To test the effect on diabetes, Tauroursodeoxycholate (300 mg/kg) was administered intraperitoneally to STZ-induced diabetic C57BL/6 mice once daily for 24 days. RESULTS: After 15 days of treatment, STZ+Tauroursodeoxycholate mice had a 43% reduction in blood glucose compared to the STZ group. This decrease may be due to an increase in insulinemia. [3] |
| Synonyms | Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, Taurolite |
| Molecular Weight | 499.7 |
| Formula | C26H45NO6S |
| Cas No. | 14605-22-2 |
| Smiles | C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](C[C@@H]3O)(C[C@H](O)CC4)04)(CC1)04)04)(CC[C@@]2([C@@H](CCC(NCCS(=O)(=O)O)=O)C)04)04 |
| Relative Density. | 1.216 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 100 mg/mL (200.12 mM), Sonication is recommended.  DMSO: 6.25 mg/mL (12.51 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 5% DMSO+95% Saline: 4.5 mg/mL (9.01 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||
Você também pode estar interessado nos seguintes produtos:
Referência
Descrição
Cond.
Price Bef. VAT